STTK vs. CMPS, PMVP, NRIX, ARCT, SYRE, RCUS, ANIP, KNSA, AKRO, and MNKD
Should you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include COMPASS Pathways (CMPS), PMV Pharmaceuticals (PMVP), Nurix Therapeutics (NRIX), Arcturus Therapeutics (ARCT), Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), ANI Pharmaceuticals (ANIP), Kiniksa Pharmaceuticals (KNSA), Akero Therapeutics (AKRO), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
COMPASS Pathways (NASDAQ:CMPS) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership.
COMPASS Pathways received 21 more outperform votes than Shattuck Labs when rated by MarketBeat users. Likewise, 76.92% of users gave COMPASS Pathways an outperform vote while only 76.32% of users gave Shattuck Labs an outperform vote.
COMPASS Pathways currently has a consensus target price of $47.40, suggesting a potential upside of 542.28%. Shattuck Labs has a consensus target price of $20.00, suggesting a potential upside of 171.00%. Given Shattuck Labs' higher possible upside, research analysts clearly believe COMPASS Pathways is more favorable than Shattuck Labs.
COMPASS Pathways has a net margin of 0.00% compared to COMPASS Pathways' net margin of -3,133.63%. Shattuck Labs' return on equity of -57.24% beat COMPASS Pathways' return on equity.
Shattuck Labs has higher revenue and earnings than COMPASS Pathways. Shattuck Labs is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
In the previous week, Shattuck Labs had 1 more articles in the media than COMPASS Pathways. MarketBeat recorded 2 mentions for Shattuck Labs and 1 mentions for COMPASS Pathways. Shattuck Labs' average media sentiment score of 1.87 beat COMPASS Pathways' score of 1.53 indicating that COMPASS Pathways is being referred to more favorably in the media.
COMPASS Pathways has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.
46.2% of COMPASS Pathways shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 4.3% of COMPASS Pathways shares are held by company insiders. Comparatively, 10.5% of Shattuck Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
COMPASS Pathways beats Shattuck Labs on 10 of the 16 factors compared between the two stocks.
Get Shattuck Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shattuck Labs Competitors List
Related Companies and Tools
